Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-2.60 · Revenue $64.09M · 2 analysts
Est. EPS $-0.41 · Revenue $16.25M · 1 analysts
Est. EPS $-0.47 · Revenue $14.83M · 1 analysts
Est. EPS $-0.49 · Revenue $15.20M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $65.3M | -3.4% | -16.3% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-81.9M | +29.4% | -49.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +93.0% | -7.0% | +7.6% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -130.7% | +27.4% | -73.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -125.4% | +26.9% | -78.0% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-32.2M | +66.7% | -39.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -49.2% | +65.6% | -66.3% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 310.7% | +77.0% | -65.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.21x | -19.3% | -2.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $280.7M | -25.5% | -5.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.84 vs -3.77 | -1.8% | -0.67 vs -0.51 | -31.5% |
| Revenue Surprise | $65.3M vs $66.2M | -1.3% | $14.4M vs $16.8M | -14.3% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 8, 2026 | Rottinghaus Scott T. | officer: Chief Medical Officer | Common Stock | D | 1,467 | $13.34 |
| Mar 11, 2026 | Vance Terry | director | Stock Option (right to buy) | A | 20,000 | $14.17 |
| Mar 11, 2026 | Russell Lesley | director | Stock Option (right to buy) | A | 20,000 | $14.17 |
| Mar 11, 2026 | Peterson Kristine | director | Stock Option (right to buy) | A | 20,000 | $14.17 |
| Mar 11, 2026 | Hata Yujiro S | director | Stock Option (right to buy) | A | 20,000 | $14.17 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Scott T. Rottinghaus | Chief Medical Officer | USD 863,706 | — | 1974 | Active |
Yat Sun Or | Chief Scientific Officer | USD 814,285 | — | 1952 | Active |
Jay R. Luly | President, Chief Executive Officer & Director | USD 742,273 | — | 1956 | Active |
Nathaniel S. Gardiner | Consultant | USD 672,675 | Male | 1954 | Active |
Brendan Luu | Chief Business Officer | USD 622,856 | Male | 1975 | Active |
Matthew Kowalsky | Chief Legal Officer & Corporate Secretary | USD 575,652 | Male | 1973 | Active |
Tara Lynn Kieffer | Chief Product Strategy Officer | USD 496,852 | Female | 1978 | Active |
Harry R. Trout | VP of Finance & Interim Principal Financial Officer | — | Male | 1969 | Active |
Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | — | Female | — | Active |
Kathleen S. Capps | Executive Director of Accounting, Controller & Interim Principal Accounting Officer | — | Female | 1985 | Active |
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.85 per share a year ago.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026. “During the quarter, we continued to build momentum across both our RSV and immunology programs,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. “Dosing began in LOTUS, our Phase.
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced it is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 2b portion of the trial will confi.
